Why Surrozen, Inc.’s (SRZN) Stock Is Up 8.75%
As of Wednesday, November 04, Surrozen, Inc.’s SRZN share price has surged by 8.75%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Commentary & Analysis
Why Surrozen, Inc.’s (SRZN) Stock Is Up 5.20%
As of Monday, October 26, Surrozen, Inc.’s SRZN share price has surged by 5.20%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Surrozen, Inc.’s (SRZN) Stock Is Up 8.75%
As of Thursday, October 22, Surrozen, Inc.’s SRZN share price has surged by 8.75%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Surrozen, Inc.’s (SRZN) Stock Is Down 5.62%
As of Friday, October 16, Surrozen, Inc.’s SRZN share price has dipped by 5.62%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Surrozen, Inc.’s (SRZN) Stock Is Down 10.68%
As of Tuesday, October 13, Surrozen, Inc.’s SRZN share price has dipped by 10.68%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | SRZN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $507.4 | $214.3 | 38% |
|
| Shares Out (Mil) | 23.1 | 53.9 | 33% |
|
| Institutional Ownership | 99.1% | 92.9% | 85% |
|
| Float (Mil) | 9.9 | 41.4 | 19% |
|
| Beta | 0.56 | 0.96 | 32% |
|
| Avg Daily Volume (000s) | 385 | 506 | 53% |
|
| Price Change (52-week) |
130.3% | 43.9% | 97% |
|
| Growth | SRZN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (49.2%) | (10.1%) | 7% |
|
| EPS (5yr) | (1.0%) | 15.8% | 30 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 5.8% | (15.7%) | 67% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 1 | 3 | |
| Current EPS | ($1.320) | ($9.140) | ($4.187) | |
| Month Ago EPS | ($1.320) | ($9.140) | ($4.187) | |
| # Rev Up | 2 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($1.295) | ($12.090) | ($3.985) | |
| Year/Year Chg | 225.1% | (71.8%) | (85.7%) | |
| Financials | SRZN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $12 | $37 | 10% |
|
| Net Income (TTM) (Mil) | ($332) | ($44) | 4% |
|
| EPS (TTM) | ($32.189) | ($1.500) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($35) | ($34) | 12% |
|
| Net Cash Flow (TTM) (Mil) | $12 | $1 | 58% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $4 | 24% |
|
| Enterprise Value (Q1) (Mil) | $205 | $172 | 26% |
|
| Valuation | SRZN | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.00 | na |
|
| P/E | na | 18.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | SRZN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (200.4%) | 67.3% | 1% |
|
| Net Margin | na | (63.5%) | na |
|
| ROA | (304.3%) | (47.5%) | 1% |
|
| ROE | 387.2% | (53.3%) | 99% |
|
| Liabilities to Assets | 289.1% | 29.6% | 99% |
|
| F-Score | 2 | 2 | 7% |
|
Surrozen, Inc. did not pass any screens on 11/5/2026.
